Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

The Lancet Diabetes and Endocrinology

Volumn 8, Issue 1, 2020, Pages 27-35

  Heerspink, Hiddo J L ^a,b   Karasik, Avraham ^c,d   Thuresson, Marcus ^e   Melzer Cohen, Cheli ^c   Chodick, Gabriel ^c,d   Khunti, Kamlesh ^f   Wilding, John P H ^g   Garcia Rodriguez, Luis Alberto ^h   Cea Soriano, Lucia ^h,i   Kohsaka, Shun ^j   Nicolucci, Antonio ^k   Lucisano, Giuseppe ^k   Lin, Fang Ju ^l,m   Wang, Chih Yuan ^l,m   Wittbrodt, Eric ⁿ   Fenici, Peter ⁿ   Kosiborod, Mikhail ^a,o  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MACCABI HEALTHCARE SERVICES   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e STATISTICON AB   (Sweden)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h Department of Pharmacoepidemiology   (Spain)

ⁱ UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^j KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k Center for Outcomes Research and Clinical Epidemiology   (Italy)

^l NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁿ ASTRAZENECA   (United Kingdom)

^o SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INTENTION TO TREAT ANALYSIS; ISRAEL; ITALY; JAPAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TAIWAN; TIME TO TREATMENT; TREATMENT RESPONSE; UNITED KINGDOM; AGED; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG THERAPY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85076615525     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(19)30384-5     Document Type: Article

References (23)

1. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
2. Perkovic, V, de Zeeuw, D, Mahaffey, KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
3. Mosenzon, O, Wiviott, SD, Cahn, A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7 (2019), 606–617.
4. Perkovic, V, Jardine, MJ, Neal, B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380 (2019), 2295–2306.
5. Kosiborod, M, Cavender, MA, Fu, AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
6. Birkeland, KI, Jorgensen, ME, Carstensen, B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
7. Kosiborod, M, Lam, CSP, Kohsaka, S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 71 (2018), 2628–2639.
8. Inker, LA, Lambers Heerspink, HJ, Mondal, H, et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis 64 (2014), 848–859.
9. Cherney, DZI, Perkins, BA, Soleymanlou, N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
10. Heerspink, HJL, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZI, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
11. Heerspink, HJL, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
12. Abdul-Ghani, MA, DeFronzo, RA, Norton, L, Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes 62 (2013), 3324–3328.
13. Udell, JA, Yuan, Z, Rush, T, Sicignano, NM, Galitz, M, Rosenthal, N, Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 137 (2018), 1450–1459.
14. Fadini, GP, Zatti, G, Baldi, I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes Metab 20 (2018), 1781–1786.
15. Fadini, GP, Solini, A, Manca, ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: a multicentre retrospective study. Diabetes Obes Metab 21 (2019), 252–260.
16. Kosiborod, M, Birkeland, KI, Cavender, MA, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study. Diabetes Obes Metab 20 (2018), 1983–1987.
17. Birkeland, KI, Bodegard, J, Norhammar, A, et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab 21 (2019), 968–974.
18. Wittbrodt, E, Chamberlain, D, Arnold, SV, Tang, F, Kosiborod, M, Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry. Diabetes Obes Metab 21 (2019), 1985–1989.
19. Selker, HP, Oye, KA, Eichler, HG, et al. A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther 95 (2014), 147–153.
20. Suissa, S, Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?. Diabetes Care 41 (2018), 6–10.
21. US Food and Drug Administration. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). https://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf. (Accessed 1 June 2019)
22. Neuen, BL, Young, T, Neal, B, et al. SGLT2 inhibition for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (2019), 845–854.
23. Nadkarni, GN, Ferrandino, R, Chang, A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40 (2017), 1479–1485.